Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients

References

• Asnis GM, Lemus CZ, Halbreich U. The desipramine cortisol test – a selective noradrenergic challenge (relationship to other cortisol tests in depressives and normals). Psychopharmacol Bull 1986; 22: 571–578
   PubMedGoogle Scholar
• De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(Suppl 4)19–25
   PubMed Web of Science ®Google Scholar
• Golden RN, Ekstrom D, Brown TM, et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 1992; 149: 1168–1175
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477–501
   PubMed Web of Science ®Google Scholar
• Laakmann G. Psychopharmaco-endocrinology and depression research]. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1988; 46: 1–220
   PubMedGoogle Scholar
• Laakmann G, Hennig J, Baghai T, Schüle C. Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology 2003; 47: 31–36
   PubMedGoogle Scholar
• Lambert JJ, Belelli D, Hill-Venning C, Peters JA. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 1995; 16: 295–303
   PubMed Web of Science ®Google Scholar
• Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev 1999; 51: 63–81
   PubMed Web of Science ®Google Scholar
• Patchev VK, Shoaib M, Holsboer F, Almeida OF. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 1994; 62: 265–271
   PubMed Web of Science ®Google Scholar
• Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almeida OF. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest 1997; 99: 962–966
   PubMedGoogle Scholar
• Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992; 6: 2311–2322
   PubMed Web of Science ®Google Scholar
• Penning TM, Burczynski ME, Jez JM, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351: 67–77
   PubMed Web of Science ®Google Scholar
• Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci 2004; 74: 3181–3197
   PubMed Web of Science ®Google Scholar
• Purdy RH, Morrow AL, Moore PH, Jr, Paul SM. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991; 88: 4553–4557
   PubMed Web of Science ®Google Scholar
• Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions?. Trends Pharmacol Sci 2003; 24: 103–106
   PubMed Web of Science ®Google Scholar
• Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003; 28: 139–168
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Reul JM, Trapp T, et al. Progesterone receptor-mediated effects of neuroactive steroids. Neuron 1993; 11: 523–530
   PubMed Web of Science ®Google Scholar
• Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 2007; 19: 213–226
   PubMed Web of Science ®Google Scholar
• Schüle C, Baghai T, Bidlingmaier M, Strasburger C, Laakmann G. Endocrinological effects of mirtazapine in healthy volunteers. Prog. Neuropsychopharmacol. Biol Psychiatry 2002a; 26: 1253–1261
   Google Scholar
• Schüle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berlin) 2002b; 163: 95–101
   PubMed Web of Science ®Google Scholar
• Schüle C, Baghai T, Rackwitz C, Laakmann G. Influence of mirtazapine on urinary free cortisol excretion in depressed patients. Psychiatry Res 2003; 120: 257–264
   PubMed Web of Science ®Google Scholar
• Schüle C, Romeo E, Uzunov DP, et al. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry 2006a; 11: 261–272
   PubMed Web of Science ®Google Scholar
• Schüle C, Baghai TC, Eser D, et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berlin) 2006b; 186: 601–611
   PubMed Web of Science ®Google Scholar
• Schüle, C, Baghai, TC, Eser, D, Schwarz, M, Bondy, B, Rupprecht, R. 2007. Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol secretion in depressed patients, Submitted.
   Google Scholar
• Ströhle A, Romeo E, Hermann B, et al. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999; 45: 274–277
   PubMed Web of Science ®Google Scholar
• Ströhle A, Pasini A, Romeo E, et al. Fluoxetine decreases concentrations of 3 alpha,5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res 2000; 34: 183–186
   PubMed Web of Science ®Google Scholar
• Ströhle A, Romeo E, Di Michele F, et al. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003; 60: 161–168
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Wunderlich U, Zaudig M, Fydrich T. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Hogrefe, Göttingen 1997
   Google Scholar